ArticleFrontiers in neurology
Associations between systemic inflammatory markers and cognitive decline in patients with early-stage Alzheimer's disease: a retrospective clinical study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence implicates systemic inflammation in Alzheimer's disease (AD)'s development and progression, yet comprehensive clinical data linking specific systemic inflammatory biomarkers to cognitive decline in early-stage AD remain limited. Objective: To evaluate the correlation between key systemic inflammatory biomarkers and cognitive decline in early-stage AD, to identify potential inflammatory indicators for risk screening and disease monitoring. Methods: In this retrospective study, 155 patients with early-stage AD and 100 matched healthy controls were enrolled between March 2020 and March 2025. Peripheral blood levels of inflammatory biomarkers, including IL-1β, IL-6, IL-8, IL-10, TNF-α, MCP-1, and CRP, were measured. Cognitive function was assessed using the MMSE and MoCA. Group comparisons, Spearman correlation analyses, and ROC curves with DeLong tests were performed. Results: The groups were comparable in baseline demographics ( Conclusion: Elevated levels of IL-6, IL-1β, and TNF-α are strongly associated with cognitive decline in early-stage AD, suggesting their utility as potential biomarkers for disease progression. A multi-marker inflammatory panel significantly enhances diagnostic accuracy, supporting the exploration of anti-inflammatory strategies for early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.